The U.S. Food and Drug Administration(FDA) is requesting manufacturers withdraw all prescription and over-the-counter Zantac (ranitidine)drugs from the market immediately. A new study in the ongoing investigation of N-Nitrosodimethylamine (NDMA) in ranitidine medications highlights the increased risk to public health.
As we’ve outlined before, NDMA is found in Zantac and is a probable human carcinogen that can cause cancer.
This latest FDA study found the NDMA levels in some ranitidine products increase over time. Third-party laboratories have confirmed that NDMA levels increase in ranitidine under normal storage conditions. Additionally, NDMA has been found to increase significantly in samples stored at higher temperatures, including temperatures the product may be exposed to during distribution and handling by consumers.
Due to the potential of exposure to unacceptable levels of NDMA, Zantac products will no longer be available for prescription or over-the-counter use.
Read the full statement from the FDA here.
If you or a loved one have been affected by Zantac or other drugs containing ranitidine, we encourage you to consult with our team as soon as possible. Our team of experienced attorneys will fight on your behalf to get the justice you deserve. Contact our team to get started on your free case evaluation.
